Difference between revisions of "Resource:9736d9b3-fbe1-45cf-a5d0-20e19038d394"
From The Embassy of Good Science
Marc.VanHoof (talk | contribs) |
Marc.VanHoof (talk | contribs) |
||
| Line 2: | Line 2: | ||
|Resource Type=Cases | |Resource Type=Cases | ||
|Title=Guest authorship, mortality reporting, and integrity in rofecoxib studies | |Title=Guest authorship, mortality reporting, and integrity in rofecoxib studies | ||
| − | |Is About=. | + | |Is About=The study by Drs Psaty and Kronmal and the accompanying Editorial by Drs DeAngelis and Fontanarosa regarding rofecoxib illustrate the recurring problem of discretionary or data-driven analysis<ref>https://jamanetwork.com/journals/jama/article-abstract/182444</ref>. |
| − | |Important Because=. | + | |Important Because=Given the possibility of selective analysis based on observed data and the risk of positive results due to chance alone, it is critical to know in detail which analyses were prespecified and when the prespecification occurred<ref>https://jamanetwork.com/journals/jama/article-abstract/182444</ref>. |
| + | |||
| + | |||
| + | |||
| + | Journal | ||
| + | |||
| + | Factual | ||
|Important For=Researchers | |Important For=Researchers | ||
}} | }} | ||
| Line 12: | Line 18: | ||
{{Tags | {{Tags | ||
|Involves=Drs Psaty; Kronmal | |Involves=Drs Psaty; Kronmal | ||
| − | |Has Location=USA | + | |Has Location=USA; United States |
|Has Virtue And Value=Honesty; Reliability | |Has Virtue And Value=Honesty; Reliability | ||
|Has Good Practice And Misconduct=Authorship; Ghost authorship; Questionable research practice | |Has Good Practice And Misconduct=Authorship; Ghost authorship; Questionable research practice | ||
|Related To Research Area=Clinical medicine | |Related To Research Area=Clinical medicine | ||
}} | }} | ||
Revision as of 15:34, 28 April 2020
ResourcesCases
Guest authorship, mortality reporting, and integrity in rofecoxib studies
What is this about?
The study by Drs Psaty and Kronmal and the accompanying Editorial by Drs DeAngelis and Fontanarosa regarding rofecoxib illustrate the recurring problem of discretionary or data-driven analysis[1].
Why is this important?
Given the possibility of selective analysis based on observed data and the risk of positive results due to chance alone, it is critical to know in detail which analyses were prespecified and when the prespecification occurred[2].
Journal
Factual
